XNAS
CLGN
Market cap18mUSD
Jun 16, Last price
1.65USD
1D
16.20%
1Q
-47.45%
Name
Collplant Biotechnologies Ltd
Chart & Performance
P/E
—
P/S
36.70
EPS
—
Div Yield, %
—
Shrs. gr., 5y
18.10%
Rev. gr., 5y
-25.98%
Revenues
515k
-95.30%
Net income
-17m
L+136.63%
CFO
-14m
L+410.06%
Earnings
Jul 16, 2025
Profile
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; AbbVie; and STEMCELL. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | ||||||||||
Revenues | 515 -95.30% | 10,959 3,565.22% | 299 -98.09% | |||||||
Cost of revenue | 12,140 | 12,475 | 10,655 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (11,625) | (1,516) | (10,356) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | (172) | |||||||||
Tax Rate | ||||||||||
NOPAT | (11,625) | (1,516) | (10,184) | |||||||
Net income | (16,609) 136.63% | (7,019) -58.10% | (16,753) -4,196.09% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 1,108 | 1,874 | ||||||||
BB yield | -1.52% | -2.03% | ||||||||
| Debt | ||||||||||
Debt current | 806 | 624 | 529 | |||||||
Long-term debt | 5,356 | 5,694 | 5,293 | |||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | (5,747) | (20,356) | (24,019) | |||||||
| Cash flow | ||||||||||
Cash from operating activities | (14,093) | (2,763) | (13,698) | |||||||
CAPEX | (483) | (954) | (1,316) | |||||||
Cash from investing activities | (539) | (1,156) | 28,922 | |||||||
Cash from financing activities | 9 | 1,108 | 1,874 | |||||||
FCF | (11,047) | (1,698) | (10,180) | |||||||
| Balance | ||||||||||
Cash | 11,909 | 26,674 | 29,653 | |||||||
Long term investments | 188 | |||||||||
Excess cash | 11,883 | 26,126 | 29,826 | |||||||
Stockholders' equity | (109,336) | (92,728) | (85,818) | |||||||
Invested Capital | 125,882 | 124,227 | 121,010 | |||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | 11,455 | 11,389 | 11,033 | |||||||
Price | 3.60 -43.66% | 6.39 -23.47% | 8.35 -48.96% | |||||||
Market cap | 41,236 -43.34% | 72,777 -21.00% | 92,128 -52.94% | |||||||
EV | 35,489 | 52,421 | 68,109 | |||||||
EBITDA | (10,587) | (414) | (9,280) | |||||||
EV/EBITDA | ||||||||||
Interest | 17 | 10 | 172 | |||||||
Interest/NOPBT | ||||||||||